J&J starts human safety trial for its Covid-19 vaccine candidate
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
  • Epaper
  • More
    • Subscribe
    • COVID-19
    • Bangladesh
    • Splash
    • Videos
    • Games
    • Long Read
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard

Wednesday
June 29, 2022

Sign In
Subscribe
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
  • Epaper
  • More
    • Subscribe
    • COVID-19
    • Bangladesh
    • Splash
    • Videos
    • Games
    • Long Read
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
WEDNESDAY, JUNE 29, 2022
J&J starts human safety trial for its Covid-19 vaccine candidate

Coronavirus chronicle

Reuters
30 July, 2020, 04:40 pm
Last modified: 30 July, 2020, 04:43 pm

Related News

  • Pfizer says 3 Covid shots protect children under 5
  • Covax calls for urgent action to close vaccine equity gap
  • Main negotiators reach 'outcome' on Covid vaccine IP waiver, WTO says
  • Britain approves Valneva's easy-to-store Covid shot
  • 95% of target population fully vaccinated: Health Minister

J&J starts human safety trial for its Covid-19 vaccine candidate

The drugmaker said it had started early-stage human trials in the United States and Belgium and would test its vaccine candidate in over 1,000 healthy adults aged 18 to 55 years, as well as adults aged 65 years and older

Reuters
30 July, 2020, 04:40 pm
Last modified: 30 July, 2020, 04:43 pm
FILE PHOTO: The company logo for Johnson & Johnson is displayed on a screen to celebrate the 75th anniversary of the company's listing at the New York Stock Exchange (NYSE) in New York, US, September 17, 2019. REUTERS/Brendan McDermid/File Photo
FILE PHOTO: The company logo for Johnson & Johnson is displayed on a screen to celebrate the 75th anniversary of the company's listing at the New York Stock Exchange (NYSE) in New York, US, September 17, 2019. REUTERS/Brendan McDermid/File Photo

Johnson & Johnson on Thursday kicked off U.S. human safety trials for its Covid-19 vaccine after releasing details of a study in monkeys that showed its best-performing vaccine candidate offered strong protection in a single dose.

When exposed to the virus, six out of six animals who got the vaccine candidate were completely protected from lung disease and five out of six were protected from infection as measured by the presence of virus in nasal swabs, according to the study published in the journal Nature.

"This gives us confidence that we can test a single-shot vaccine in this epidemic and learn whether it has a protective effect in humans," Dr Paul Stoffels, J&J's chief scientific officer, told Reuters in a telephone interview.

The drugmaker said it had started early-stage human trials in the United States and Belgium and would test its vaccine candidate in over 1,000 healthy adults aged 18 to 55 years, as well as adults aged 65 years and older.

The U.S. government is backing J&J's vaccine effort with $456 million in funding as part of a spending spree aimed at speeding production of a vaccine to end the pandemic, which has infected millions and killed more than 660,000 people.

Stoffels said prior tests of this type of vaccine in other diseases found that a second shot significantly increases protection. But in a pandemic a single-shot vaccine has a significant advantage, sidestepping a lot of the logistical issues involved in getting people to come back for their second dose.

The company plans to take up the question of one or two doses in its phase 1 trial.

Depending on those results, J&J plans to start large-scale, phase 3 testing with a single-shot regimen in the second half of September. Around the same time, the company will start a parallel phase 3 study testing a two-shot regimen of the vaccine, Stoffels said.

J&J's vaccine uses a common cold virus known as adenovirus type 26 or Ad26 to ferry coronavirus proteins into cells in the body, causing the body to mount an immune defense against the virus.

In the monkey study, scientists from J&J and Harvard's Beth Israel Deaconess Medical Center studied seven different potential vaccines in 32 animals and compared the results to 20 control animals who got placebo shots.

Six weeks later, all of the animals were exposed to the SARS-CoV-2 virus. All 20 animals that received the placebo developed high levels of virus in their lungs and nasal swabs.

In the best-performing candidate, which J&J selected for human testing, none of the animals had virus in their lungs and only one showed low levels of virus in nasal swabs. Lab tests showed they all had developed antibodies capable of neutralizing the virus after a single shot.

"This study shows that even just a single immunization with the Ad26 vaccine leads to neutralizing antibody responses and robust protection of monkeys against Covid-19," said Dr Dan Barouch, a vaccine researcher at Beth Israel Deaconness who led the research in collaboration with J&J.

J&J shares were up nearly 2 percent at $149.72 before the bell on Thursday.

Top News

Johnson & Johnson / covid-19 vaccine

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Bangladesh expects $5.5b from WB, IMF in budget support
    Bangladesh expects $5.5b from WB, IMF in budget support
  • Advance tax hits construction sector hard: Entrepreneurs
    Advance tax hits construction sector hard: Entrepreneurs
  • Representational Image: Collected
    ABB concerned over mandatory tax return submission for SME loans

MOST VIEWED

  • David E Adler. Sketch: TBS
    Who managed Covid-19 best, and why?
  • People line up at a nucleic acid testing station, following the coronavirus disease (COVID-19) outbreak, in Beijing, China, June 16, 2022. REUTERS/Thomas Peter/File Photo
    China slashes Covid quarantine time for international travellers
  • Covid-19 deaths were reported from Gorakhpur, Jalaun, Bulandshahr, Kannauj, Sonbhadra, Gonda, Bhadohi, Basti, Kushinagar and Mau (HT Photo)
    India sees 45% jump in a day with 17,073 new Covid cases
  • A healthcare worker collects the nasal sample of a policeman for Covid testing in Jammu on Wednesday. (ANI Photo)
    India’s daily Covid tally declines with 15,940 cases, 20 new deaths added
  • A medical worker takes a swab sample from a person for a nucleic acid test at a makeshift testing site, amid the coronavirus disease (Covid-19) outbreak, in Beijing, China May 23, 2022. REUTERS/Tingshu Wang
    Beijing says will reopen primary, secondary schools as Covid cases recede
  • Anthony Fauci  Photo: Collected
    Top US medical expert Fauci says he is 'example' for Covid-19 vaccinations

Related News

  • Pfizer says 3 Covid shots protect children under 5
  • Covax calls for urgent action to close vaccine equity gap
  • Main negotiators reach 'outcome' on Covid vaccine IP waiver, WTO says
  • Britain approves Valneva's easy-to-store Covid shot
  • 95% of target population fully vaccinated: Health Minister

Features

Abortion is a part of healthcare. Photo: Bloomberg

Abortion is healthcare and women’s rights are human rights

16h | Panorama
Prashanta Kumar Banerjee. Sketch: TBS

'Public Asset Management Company can be an additional tool to curb bad loans'

18h | Interviews
Aid boats navigate through the different waters of Jamalganj Upazila, giving aid to flood victims.  Photo: Masum Billah

Bandits, hunger and snakes: Flood victims pass sleepless nights

20h | Panorama
Redmi 10C- Best Budget smartphone with one (big) compromise

Redmi 10C- Best Budget smartphone with one (big) compromise

1d | Brands

More Videos from TBS

Why teachers are being humiliated again and again?

Why teachers are being humiliated again and again?

8h | Videos
After Bangabandhu Bridge, will Padma Bridge change economy again?

After Bangabandhu Bridge, will Padma Bridge change economy again?

9h | Videos
 Fuel for non-essential vehicles banned in Sri Lanka

Fuel for non-essential vehicles banned in Sri Lanka

11h | Videos
Christiano Ronaldo to join Chelsea?

Christiano Ronaldo to join Chelsea?

11h | Videos

Most Read

1
Padma Bridge from satellite. Photo: Screengrab
Bangladesh

Padma Bridge from satellite 

2
Photo: TBS
Bangladesh

Motorcycles banned on Padma Bridge 

3
Japan cancels financing Matarbari coal project phase 2
Bangladesh

Japan cancels financing Matarbari coal project phase 2

4
Photo: Courtesy
Corporates

Gree AC being used in all parts of Padma Bridge project

5
Photo: TBS
Infrastructure

Gains from Padma Bridge to cross $10b, hope experts

6
Desco wanted to make a bold statement with their new head office building, a physical entity that would be a corporate icon. Photo: Courtesy
Habitat

Desco head office: When commitment to community and environment inspires architecture

EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2022
The Business Standard All rights reserved
Technical Partner: RSI Lab
BENEATH THE SURFACE
Workers unload boats and stockpile sacks of paddy at the BOC Ghat paddy market on the bank of the River Meghna in Brahmanbaria’s Ashuganj, the largest paddy market in the eastern part of the country. This century-old market sells paddies worth Tk5-6 crore a day during the peak season. PHOTO: RAJIB DHAR

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net